Status:
COMPLETED
Intranasal Heparin Tolerability Study
Lead Sponsor:
Joshua Sharp
Conditions:
Covid19
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
The investigators are investigating the tolerability of Heparin Sodium (porcine) administered topically via a nasal spray. This agent is being investigated as a potential prophylactic treatment to pre...
Detailed Description
Study Objectives This exploratory clinical trial is designed to assess tolerability of increasing doses of intranasally administered heparin sodium in saline solution. Baseline values for aPTT and co...
Eligibility Criteria
Inclusion
- Normal, healthy adults aged 18 to 65 years
Exclusion
- Allergy to Heparin
- Currently taking any prescription blood thinners or anti-coagulants, or currently taking any intranasal medication
- Known history of anemia, thrombocytopenia, or other blood disorder
- Autoimmune disorders
- Known history of Neurologic/Psychiatric disorders
- Report of an active infection
- Subject is pregnant or breast-feeding, or is expecting to conceive during the study.
- NOTE: Subjects will be instructed to abstain from alcohol for the duration of the study.
Key Trial Info
Start Date :
October 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04490239
Start Date
October 9 2020
End Date
November 18 2020
Last Update
April 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Mississippi National Center for Natural Products Research
University, Mississippi, United States, 38677-1848